---

$0.71

+0.1080 ( +17.00% ) 4.5M

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Analyst Insights

---

You need to login to view this content.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-07-02	Sale	-8972.00	Alleva Lawrence M
2024-06-12	Sale	-55000.00	Hack Andrew A. F.
2024-06-12	Sale	-55000.00	Hege Kristen
2024-06-12	Sale	-55000.00	MOTT DAVID M
2024-06-12	Sale	-55000.00	Dere Willard H
2024-06-12	Sale	-55000.00	Alleva Lawrence M
2024-06-12	Sale	-55000.00	Diaz Allene M.
2024-06-12	Sale	-55000.00	Protopapas Anna
2024-04-03	Sale	-3996.00	Alleva Lawrence M
2024-01-17	Sale	-9375.00	Lowinger Timothy B

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.